Freire de Carvalho Jozélio, Amoedo Martinez Ana Tereza
Núcleo de Pesquisa em Doenças Crônicas não Transmissíveis (NUPEC), School of Nutrition from the Federal University of Bahia, Salvador, Bahia, Brazil.
Universidade Estadual de Feira de Santana, Feira de Santana, Bahia, Brazil.
Eur J Rheumatol. 2025 May 30;12(2):1-5. doi: 10.5152/eurjrheum.2025.24080.
Hyperprolactinemia is frequent in rheumatic diseases. Bromocriptine (BRC) is an antagonist of pro- lactin and was studied in a few rheumatic diseases with controversial results. The aim of the present study was to review articles on BRC in rheumatic diseases. Articles on lupus, rheumatoid arthritis, pso- riatic arthritis (PsA), and reactive arthritis were found. Fourteen articles were found. In lupus, 5 articles evaluated BRC in a 2.5-7.5 mg/day dosage. The follow-up varied from 6 to 14 months. They showed improvement in lupus disease activity (Lupus Disease Activity Index or Lupus activity measure scores) in 4/5; a trend was verified in another article, 1/5, and one study evaluated improvement in the mood of the systemic lupus erythematosus patients. In RA, there are 4 articles with 119 patients. The BRC dosage ranged from 5 mg/day to 10 mg TID. About 2/4 of the articles showed improvements [morn- ing stiffness and Health Assessment Questionnaire (HAQ)], and 2/4 did not show any difference. Regarding PsA and reactive arthritis, 5 articles with 43 patients were found. The BRC dose varied from 2.5 to 30 mg/day. All studies showed improvements of the studied diseases. Side effects were mild and infrequent. In conclusion, BRC seems to be efficacious in a few rheumatic diseases (lupus, PsA, RA, and Reiter's), with mild side effects. Future studies with a larger number of participants and in other rheumatic diseases are needed.
高催乳素血症在风湿性疾病中很常见。溴隐亭（BRC）是一种催乳素拮抗剂，已在一些风湿性疾病中进行了研究，但结果存在争议。本研究的目的是回顾关于溴隐亭在风湿性疾病中的文章。发现了关于狼疮、类风湿关节炎、银屑病关节炎（PsA）和反应性关节炎的文章。共找到14篇文章。在狼疮方面，5篇文章评估了每日2.5 - 7.5毫克剂量的溴隐亭。随访时间从6个月到14个月不等。其中4/5的研究显示狼疮疾病活动度（狼疮疾病活动指数或狼疮活动度测量评分）有所改善；另一篇文章显示有改善趋势（1/5），还有一项研究评估了系统性红斑狼疮患者情绪的改善情况。在类风湿关节炎方面，有4篇文章涉及119名患者。溴隐亭剂量范围为每日5毫克至每日10毫克，每日三次。约2/4的文章显示有改善（晨僵和健康评估问卷（HAQ）），2/4未显示出任何差异。关于银屑病关节炎和反应性关节炎，找到5篇文章涉及43名患者。溴隐亭剂量从每日2.5毫克至30毫克不等。所有研究均显示所研究疾病有改善。副作用轻微且不常见。总之，溴隐亭似乎对一些风湿性疾病（狼疮、银屑病关节炎、类风湿关节炎和赖特综合征）有效，且副作用轻微。未来需要开展涉及更多参与者以及针对其他风湿性疾病的研究。
